TOI vs AMS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TOI Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to The Oncology Institute, Inc. Common Stock (TOI) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while AMS counters with relative strength in Valuation. Fundamentally, TOI trades at N/M Forward P/E with -4.4% operating margin (+41.2% YoY revenue) versus AMS at 44.6x Forward P/E and -7.4% operating margin (+19.2% YoY). In options structure, TOI sits in SURGE (35th %ile IV; Dealer Gamma Walls on Pro) against AMS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | TOI Revenue | AMS Revenue | TOI Op. Margin | AMS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $20M | N/A | 9.4% | AMS |
| FY2019 | N/A | $20M | N/A | 7.5% | AMS |
| FY2020 | $190M | $20M | -4.4% | -53.1% | TOI |
| FY2021 | $200M | $20M | -22.6% | 7.7% | AMS |
| FY2022 | $250M | $20M | -32.5% | 12.3% | AMS |
| FY2023 | $320M | $20M | -23.8% | 1.3% | AMS |
| FY2024 | $390M | $30M | -15.3% | -9.9% | AMS |
| FY2025 | $500M | $30M | -7.2% | -12.8% | TOI |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TOI | AMS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $506.9M | $7.2M | Larger Scale | TOI |
| Trailing P/E Ratio Valuation | N/M | 44.6x | Lower Multiple | AMS |
| Forward P/E Ratio Valuation | N/M | 44.6x | Lower Multiple | AMS |
| Revenue Growth (YoY) Growth | +41.2% | +19.2% | Higher Growth | TOI |
| Operating Margin (TTM) Profitability | -4.4% | -7.4% | Higher Margin | TOI |
| Net Profit Margin Profitability | -8.0% | -5.8% | Higher Margin | AMS |
| Return on Equity (ROE) Capital Efficiency | -651.7% | -12.1% | Higher ROE | AMS |
| 52-Week Range Position Momentum | 65% ($2โ$7) | 6% ($1โ$2) | Stronger Trend | TOI |
| Beta / 30D Volatility Risk Regime | 1.66ฮฒ ยท 73% Vol | 0.18ฮฒ ยท 46% Vol | Lower Realized Risk | AMS |
| Unified Institutional Score Composite Signal | 53.5 / 100 (HOLD) | 33.8 / 100 (SELL) | Higher Composite | TOI |